|
|
|
|
The observed incidence of CHF in patients with MS who received a mean cumulative dose of 60.5 mg/m2 MITO was <0.20%. Continued monitoring of patients with MS who are receiving MITO is needed to determine whether the incidence of CHF increas es with higher cumulative doses and prolonged follow-up. |
|